顺铂联合恩格菲胸腔内灌注治疗肺癌胸腔积液的疗效观察  

Efficacy of cisplatin combined with staphylococcin aureus in pleural effusion of lung cancer treated with intrathoracic perfusion

作　　者：李兆金 满华 

机构地区：[1]山东省枣庄市王开传染病医院,277500

出　　处：《中国医学创新》2010年第26期45-46,共2页Medical Innovation of China

摘　　要：目的观察顺铂联合恩格菲(金葡素注射液)胸腔内灌注治疗肺癌胸腔积液的疗效和毒副作用。方法 460例肺癌患者随机分为顺铂组和顺铂+恩格菲组,顺铂组为胸腔内灌注生理盐水40 ml+顺铂50 mg,顺铂+恩格菲组为生理盐水40 ml+顺铂50 mg+恩格菲8 mg,每隔72 h重复上述操作一次,连续2～3次。结果与顺铂组比较,顺铂+恩格菲组总有效率增加26.1%,Karnofsky评分上升人数及其百分比均明显升高,P<0.05,差异有统计学意义。两组患者均无严重的毒副作用发生。结论顺铂联合恩格菲胸腔内灌注治疗肺癌胸腔积液有明显的临床疗效,能改善患者的生活质量,毒副作用小。Objective To observe efficacy and side effects of cisplatin combined with staphylococcin aureus in pleural effusion of lung cancer treated with intrathoracic perfusion. Methods 460 cases of lung cancer patients were randomly divided into eisplatin group and cisplatin ＋ staphylococcin aureus preparation group, cisplatin group：normal saline 40 ml ＋ eispl- atin 50 mg;cisplatin ＋ staphylococcin aureus preparation group： normal saline 40 ml ＋ cisplatin 50 mg＋ staphylococcin au- reus preparation 8 mg, every 72 h repeat once, for 2 to 3 times. Results Compared with cisplatin, in cisplatin ＋ staphylococcin aureus Preparation group total effective rate was increased 26.1%, Karnofsky score increased the number and percentage sig- nificantly （P 〈0.05 ） ,and there was statistically significant. Two groups of patients had no serious toxic side effects. Conclu- sion There is significant clinical efficacy about cisplatin combined with staphylococcin aureus in pleural effusion of lung cancer treated with intrathoracic perfusion. And it improve the quality of life of patients, has small side effects.

关 键 词：肺癌 胸腔积液 顺铂 恩格菲 

分 类 号：R734.2[医药卫生—肿瘤]